Diruthenium(ii,iii) paddlewheel complexes: effects of bridging and axial ligands on anticancer properties

被引:18
|
作者
Tolbatov, Iogann [1 ]
Barresi, Elisabetta [2 ]
Taliani, Sabrina [2 ]
La Mendola, Diego [2 ]
Marzo, Tiziano [2 ]
Marrone, Alessandro [3 ]
机构
[1] Barcelona Inst Sci & Technol, Inst Chem Res Catalonia ICIQ, Ave Paisos Catalans 16, Tarragona 43007, Spain
[2] Univ Pisa, Dept Pharm, Via Bonanno Pisano 6, I-56126 Pisa, Italy
[3] Univ G dAnnunzio, Dept Pharm, Via Vestini 31, I-66100 Chieti, Italy
关键词
NONSTEROIDAL ANTIINFLAMMATORY DRUGS; IN-VITRO; TETRAACETATE COMPLEXES; IBUPROFEN; COMPOUND; NAPROXEN; PH; PROLIFERATION; RU2CL(IBP)(4); METALLODRUGS;
D O I
10.1039/d3qi00157a
中图分类号
O61 [无机化学];
学科分类号
070301 ; 081704 ;
摘要
This article provides an overview of the application of diruthenium(ii,iii) paddlewheel complexes for anticancer purposes. The use of this coordinative construct is indeed attractive because it provides an excellent opportunity to combine the pharmacological properties of the dimetallic ruthenium center with those derived from the specific choice of ligands bearing a carboxylic function capable of coordination towards the Ru-Ru core. Indeed, the combination of carboxylate ligands with specific anticancer properties and the dimetallic center permits the production of new entities endowed with improved biological profiles. Additionally, these systems allow the simultaneous multiple deliveries of a drug to the target site. Nevertheless, in order to obtain the desired effects, it is mandatory to consider some relevant chemico-physical aspects such as the steric hindrance of the ligands or the possibility of their release under specific biological conditions that should be taken into account in the design of effective complexes. Accordingly, through various examples from the literature, the key features of this family of unconventional compounds are summarized here, also providing useful hints for the design of improved diruthenium(ii,iii) paddlewheel complexes.
引用
收藏
页码:2226 / 2238
页数:13
相关论文
共 50 条
  • [31] Synthesis, Characterization and Anticancer Studies of Rh(I), Rh(III), Pd(II) and Pt(II) Complexes Bearing A Dithiooxamide Ligand
    Askari, Banafshe
    Rudbari, Hadi Amiri
    Valente, Andreia
    Bruno, Giuseppe
    Micale, Nicola
    Shivalingegowda, Naveen
    Krishnappagowda, Lokanath Neratur
    CHEMISTRYSELECT, 2020, 5 (02): : 810 - 817
  • [32] Stable Anticancer Gold(III)-Porphyrin Complexes: Effects of Porphyrin Structure
    Sun, Raymond Wai-Yin
    Li, Carrie Ka-Lei
    Ma, Dik-Lung
    Yan, Jessie Jing
    Lok, Chun-Nam
    Leung, Chung-Hang
    Zhu, Nianyong
    Che, Chi-Ming
    CHEMISTRY-A EUROPEAN JOURNAL, 2010, 16 (10) : 3097 - 3113
  • [33] Designing anticancer copper(II) complexes by optimizing 2-pyridine-thiosemicarbazone ligands
    Deng, Jungang
    Yu, Ping
    Zhang, Zhenlei
    Wang, Jun
    Cai, Jinhua
    Wu, Na
    Sun, Hongbin
    Liang, Hong
    Yang, Feng
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 158 : 442 - 452
  • [34] New Nanostructured Materials Based on Mesoporous Silica Loaded with Ru(II)/Ru(III) Complexes with Anticancer and Antimicrobial Properties
    Marinescu, Gabriela
    Culita, Daniela C.
    Mocanu, Teodora
    Mitran, Raul-Augustin
    Petrescu, Simona
    Stan, Miruna S.
    Chifiriuc, Mariana C.
    Popa, Marcela
    PHARMACEUTICS, 2023, 15 (05)
  • [35] Copper (II) complexes with N, S donor pyrazole-based ligands as anticancer agents
    Ghorbanpour, Monireh
    Soltani, Behzad
    Mota, Ali
    Sardroodi, Jaber Jahanbin
    Aghdam, Elnaz Mehdizadeh
    Shayanfar, Ali
    Molavi, Ommoleila
    Mohammad-Rezaei, Rahim
    Ebadi-Nahari, Mostafa
    Ziegler, Christopher J.
    BIOMETALS, 2022, 35 (05) : 1095 - 1111
  • [36] Anticancer evaluation of ruthenium(III) complexes with N-donor ligands tethered to coumarin or uracil moieties
    Gramni, Larusha
    Vukea, Nyeleti
    Chakraborty, Abir
    Samson, William John
    Dingle, Laura Margaret Kirkpartick
    Xulu, Bheki
    de la Mare, Jo-Anne
    Edkins, Adrienne Lesley
    Booysen, Irvin Noel
    INORGANICA CHIMICA ACTA, 2019, 492 (98-107) : 98 - 107
  • [37] Homo and heteromultimetallic complexes containing a group 8 transition metal and μ-diphosphine bridging ligands involved in anticancer research: A review
    Roufosse, Basile
    Serbu, Christi
    Marschner, Christoph
    Prince, Sharon
    Blom, Burgert
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 274
  • [38] Homo- and heterometallic complexes of Zn(ii), {Zn(ii)Au(i)}, and {Zn(ii)Ag(i)} with pentadentate Schiff base ligands as promising anticancer agents
    Zhivkova, Tania
    Culita, Daniela C.
    Abudalleh, Abedulkadir
    Dyakova, Lora
    Mocanu, Teodora
    Madalan, Augustin M.
    Georgieva, Milena
    Miloshev, George
    Hanganu, Anamaria
    Marinescu, Gabriela
    Alexandrova, Radostina
    DALTON TRANSACTIONS, 2023, 52 (35) : 12282 - 12295
  • [39] Anticancer and antibacterial potential of robust Ruthenium(II) arene complexes regulated by choice of α-diimine and halide ligands
    Zanda, Emanuele
    Busto, Natalia
    Biancalana, Lorenzo
    Zacchini, Stefano
    Biver, Tarita
    Garcia, Begona
    Marchetti, Fabio
    CHEMICO-BIOLOGICAL INTERACTIONS, 2021, 344
  • [40] Synthesis, characterization, and anticancer properties of iminophosphineplatinum(II) complexes containing boronate esters
    St-Coeur, Patrick-Denis
    Kinley, Samantha
    Vogels, Christopher M.
    Decken, Andreas
    Morin, Pier Jr.
    Westcott, Stephen A.
    CANADIAN JOURNAL OF CHEMISTRY, 2017, 95 (02) : 207 - 213